SciBase announces collaboration to detect skin barrier dysfunction in infants

The goal of the collaboration is to develop and validate an AI-based solution that detects skin barrier dysfunction and may be able to predict an infant’s risk of developing atopic dermatitis. The method will be based on SciBase’s Electrical Impedance Spectroscopy (EIS) technology and specifically for the portable Nevisense Go device. The collaboration will start… SciBase announces collaboration to detect skin barrier dysfunction in infants weiterlesen

New article discusses EIS as a potential clinical measure of skin barrier integrity

The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin’s resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been… New article discusses EIS as a potential clinical measure of skin barrier integrity weiterlesen

New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy

STOCKHOLM, SWEDEN, – October 26, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named “Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin… New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy weiterlesen

The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2023:

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 18, 2022. The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2023 in Stockholm. Shareholders who… The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2023: weiterlesen

Nevisense detects skin barrier damage in mice caused by household detergents

The use of professional and household cleaning agents is associated with an increased risk of developing allergic disorders. In line with this, impairment of the epithelial barrier is also associated with the development of allergic disorders. The aim of the study was to utilize Nevisense and Electrical Impedance Spectroscopy (EIS) to assess the effect of… Nevisense detects skin barrier damage in mice caused by household detergents weiterlesen

FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers

Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies. „The standards would have to be set very high for new products, especially those intended for consumers,“ said FDA panelist Murad Alam, MD, a dermatologist from Northwestern University, Chicago, Illinois. The… FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers weiterlesen

US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy

The aim of the study was to investigate the impact Electrical Impedance Spectroscopy (EIS) has on clinical decision-making for atypical pigmented skin lesions (PSLs) when compared to other diagnostic tools such as dermoscopy. Dermatologists, dermatology residents, and medical students completed an online survey eliciting their biopsy decisions for 24 atypical PSLs of varying histopathological diagnosis.… US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy weiterlesen

Interim Report Q1 2022

The first quarter in figures Net sales amounted to TSEK 4,260 (2,562). The loss after tax amounted to TSEK 9,736 (8,153). The loss per share amounted to SEK 0.14 (0.15). The cash flow from current operations was negative in the amount of TSEK 10,512 (9,473). The gross margin reached 62.8% (52.7%). Electrode sales volume increased by 33% and reached… Interim Report Q1 2022 weiterlesen

SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022

„It has been a busy start to the year and we see an exciting year in front of us with US growth and progress with the skin barrier application.,“ says Simon Grant, CEO SciBase. For more information please contact:Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email:   Certified Advisor:Vator Securities Tel: +46 8 580 065… SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022 weiterlesen

German study shows clinical benefit of Nevisense

The study looked at the real-life clinical effectiveness of Electrical Impedance Spectroscopy (EIS) when using Nevisense to detect malignancies in an everyday clinical setting. In summary, the study clinic showed a reduction in the number of unnecessary excisions of 47%, while still detecting 100% of melanomas. Clinicians combine Nevisense with visual and dermatoscopic examinations to… German study shows clinical benefit of Nevisense weiterlesen

Besucheradresse